Erasca Reports Third Quarter 2026 Business Updates and Financial Results
Globe Newswire•12/11/2026•16:01 ET
0
Key Highlights
- ➤Cash, equivalents, and marketable securities reached $947.8 million at September 30, 2026
- ➤FDA granted ERAS-0015 Fast Track Designation for metastatic pancreatic adenocarcinoma
- ➤Upsized public offering raised approximately $632.5 million in gross proceeds
- ➤Net loss widened to $51.3 million, or $(0.15) per share, in Q3 2026
- ➤Three potentially registration-enabling pancreatic and lung cancer trials advancing toward 2027
Expert Statements
Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca
“The emerging clinical profile of ERAS-0015 continues to support its potential as a foundational therapy across RAS-mutant cancers, both as a monotherapy and backbone for combination regimens.”
Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca
“We are rapidly advancing toward three potentially registration-enabling trials in pancreatic and lung cancers.”
Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca
“We are pleased that ERAS-0015 received Fast Track Designation for metastatic pancreatic cancer, which offers an opportunity for closer engagement with the FDA as we progress the program.”
Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca
“With a strengthened balance sheet and experienced R&D leadership, we believe that we are positioned to execute our near-term milestones and advance programs addressing high unmet needs for patients with RAS-mutant cancers.”
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling trials in pancreatic and lung cancers
Updated ERAS-0015 monotherapy and nonclinical ERAS-0015/ERAS-4001 combination data to be presented at ENA; expect preliminary ERAS-4001 data in H2 2026 and ERAS-0015 data in H1 2027
Get started
Create a free account to read the full story.